Barclays has initiated coverage on Kymera Therapeutics Inc (KYMR) with an Overweight rating, reflecting the firm's initial assessment of the company's investment potential. The action took place on September 16, 2025, with the stock currently priced at $66.42.
Kymera Therapeutics, a biotechnology firm based in Watertown, Massachusetts, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins. The company operates a targeted protein degradation platform aimed at treating a broad range of diseases, particularly in the field of immunology. As of November 20, 2025, Kymera has a market capitalization of $4.7 billion and an earnings per share (EPS) of -3.59.
Looking ahead, the company is expected to report its next earnings results on August 10, 2026, with an EPS estimate of -1.04 and projected revenue of $10.2 million. Recent earnings performance has shown variability, with a Q3 2025 EPS of -0.94 against an estimate of -0.82, reflecting a 14.6% surprise to the downside.
Analyst consensus indicates a Buy rating, with 12 Strong Buy and 16 Buy ratings among 29 total ratings. The move underscores Barclays' confidence in Kymera's growth prospects as it continues to advance its clinical programs.